Nido Biosciences’ lead drug hits a previously undrugged pocket as a way to potentially treat the rare neuromuscular disorder spinal and bulbar muscular atrophy. The startup’s tech platform screens neurons to find targets for new neurological disorder drugs.
The Seattle-based company is one of several that have raised venture capital and equity investment funding this week.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The firm said the new round increased its private deal capacity to nearly $1 billion and total assets under management to around $2.5 billion.
5AM Ventures and RA Capital Management led the round. The company is developing hematopoietic stem cells engineered to be protected from targeted immunotherapies.
The venture capital firm said Wednesday that it had closed the two new funds - 5AM Ventures VI and 5AM Opportunities I - that will respectively be used for new investments and existing portfolio companies.
The latest fund raise brings the total funding the company has received since May to $88 million, which it will use to develop CAAR-T therapies, similar to CAR-Ts used in cancers.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
The company plans to file an IND in the second half of 2019. The company CEO says the "CAAR-T" therapies may avoid some of the potentially fatal toxicity risks of CAR-Ts for blood cancers.
5 AM Ventures previously raised $250 million in 2013 for 5AM Ventures IV
Its core science comes from Harvard Stem Cell Institute researcher Richard Gregory, who focuses on the function of miRNA in disease manifestation. We're guessing Homology Medicines is in this field as well.
After one year at biotech startup Solstice Biologics, Third Rock vet Lou Tartaglia's back in venture land - having joined 5AM Ventures.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Despite a downward slide over the last several quarters, things seem to be looking up for venture capital investments in the life sciences — at least anecdotally. The latest example is a new $250 million fund raised by 5AM Ventures, which invests in early-stage life science companies, primarily those focused on the discovery and development […]